Company intelligence / Profile preview

Salient Pharmaceuticals

Ownership: Private
Development stage: Phase 2

Overview

A Phase 1 clinical trial (NCT02018653) for CASAD in treating severe diarrhea (Grade 3 or 4) in cancer patients was terminated. The trial aimed to evaluate if calcium alumina-silicate could help stop diarrhea and decrease its duration in cancer patients.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

CASAD

Phase 2

Indications: Cancer therapy-induced gastrointestinal side effects

Partnerships

Texas EnteroSorbents, Inc.

Beyond the preview

Go deeper on Salient Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Salient Pharmaceuticals.

Explore the full profile